Suscribirse

Out-of-season recollection of drug use for seasonal IgE-mediated rhinitis: Useful but an overestimation - 18/08/11

Doi : 10.1016/j.jaci.2005.01.032 
Uffe Bodtger, PhD , Hans-Jørgen Malling, MD, Lars K. Poulsen, PhD
From the Allergy Clinic, National University Hospital 

Reprint requests: Uffe Bodtger, MD, Allergy Clinic 7551, National University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.

Copenhagen, Denmark

Abstract

Background

The history of seasonal, IgE-mediated (allergic) rhinitis is often obtained postseasonally as a retrospective assessment. It is not known whether recollected drug use is representative for the in-seasonal medication history.

Objectives

To investigate the agreement between in-seasonal and out-seasonal reports on drugs and drug doses, and to investigate whether retrospective assessment was sufficiently sensitive to detect the effect of intervention.

Material and methods

Thirty-five patients allergic to birch pollen were allocated to allergen-specific immunotherapy (SIT) or placebo in a double-blind study. Drug use was recorded daily during the season 2000 and out-seasonally 6 months after the seasons 1999 and 2000. The mean daily drug use was transformed into a 4-point categorical scale for simplicity and was calculated for the out-seasonal rating and for 6 in-seasonal periods of different durations. In-seasonal and postseasonal ratings were compared with the Cohen weighted κ (κw).

Results

We observed a high level of agreement between in-seasonal and retrospective reports of drugs used (κw>0.60) and drug doses (κw>0.50). The highest agreement was observed for the in-seasonal day, week, or 2 weeks with the highest drug intake. Out-seasonal ratings significantly overestimated the daily oral and nasal antihistamine use compared with in-seasonal periods >2 weeks. Despite being comparable pretreatment, only the SIT group had a significant decrease in recollected total drug use during SIT.

Conclusion

Out-seasonal recollection of hay fever drugs represented a period of a maximum 14 days. It appeared sufficiently sensitive to detect the effect of intervention.

El texto completo de este artículo está disponible en PDF.

Key words : IgE, rhinitis, allergy, retrospective, recollection, immunotherapy, medication, birch

Abbreviations used : DD, SAR, SIT


Esquema


 Supported by a grant from the Danish Allergy Research Center, Denmark.


© 2005  American Academy of Allergy, Asthma and Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 115 - N° 4

P. 786-790 - avril 2005 Regresar al número
Artículo precedente Artículo precedente
  • Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge
  • A. Janneke Ravensberg, Fabio L.M. Ricciardolo, Annemarie van Schadewijk, Klaus F. Rabe, Peter J. Sterk, Pieter S. Hiemstra, Thais Mauad
| Artículo siguiente Artículo siguiente
  • An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment
  • Eli O. Meltzer, Robert B. Berkowitz, Elliott B. Grossbard

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.